MJFF will be able to use H1’s platform to run more diverse clinical trials
Parkinson’s disease has been notoriously been difficult to cure. Nearly one million people in the United States alone, and over six million people worldwide, have it, making it the second-most common neurodegenerative disease after Alzheimer’s; yet, representation of patients from marginalized racial and ethnic groups in Parkinson disease trials has been low, limiting the the use of therapeutic options. H1 is a … [Read more]
Go to Source of this post
Author Of this post:
Title Of post:
H1 and The Michael J. Fox Foundation team up to fuel Parkinson’s research
Author Link: {authorlink}